Vicky Mody1, Shashidharamurthy Taval2, Joanna Ho1, Savannah Wills1, Ahmed Mawri1, Latasha Lawson1, Maximilian C C J C Ebert3, Guillaume M Fortin3, Srujana Rayalam1. 1. Department of Pharmaceutical Sciences, School of Pharmacy, Philadelphia College of Osteopathic Medicine - Georgia Campus, Suwanee, GA, USA. 2. Department of Pharmaceutical Sciences, School of Pharmacy, Philadelphia College of Osteopathic Medicine - Georgia Campus, Suwanee, GA, USA. rangaiahsh@pcom.edu. 3. Chemical Computing Group, 910-1010 Sherbrooke W, Montreal, QC, H3A 2R7, Canada.
Abstract
Emerging outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is a major threat to public health. The morbidity is increasing due to lack of SARS-CoV-2 specific drugs. Herein, we have identified potential drugs that target the 3-chymotrypsin like protease (3CLpro), the main protease that is pivotal for the replication of SARS-CoV-2. Computational molecular modeling was used to screen 3987 FDA approved drugs, and 47 drugs were selected to study their inhibitory effects on SARS-CoV-2 specific 3CLpro enzyme in vitro. Our results indicate that boceprevir, ombitasvir, paritaprevir, tipranavir, ivermectin, and micafungin exhibited inhibitory effect towards 3CLpro enzymatic activity. The 100 ns molecular dynamics simulation studies showed that ivermectin may require homodimeric form of 3CLpro enzyme for its inhibitory activity. In summary, these molecules could be useful to develop highly specific therapeutically viable drugs to inhibit the SARS-CoV-2 replication either alone or in combination with drugs specific for other SARS-CoV-2 viral targets.
Emerging outbreak of severe acute respiratory syndrome coronavirus-2 (n class="Species">SARS-CoV-2) infection is a major threat to public health. The morbidity is increasing due to lack of SARS-CoV-2 specific drugs. Herein, we have identified potential drugs that target the 3-chymotrypsin like protease (3CLpro), the main protease that is pivotal for the replication of SARS-CoV-2. Computational molecular modeling was used to screen 3987 FDA approved drugs, and 47 drugs were selected to study their inhibitory effects on SARS-CoV-2 specific 3CLpro enzyme in vitro. Our results indicate that boceprevir, ombitasvir, paritaprevir, tipranavir, ivermectin, and micafungin exhibited inhibitory effect towards 3CLpro enzymatic activity. The 100 ns molecular dynamics simulation studies showed that ivermectin may require homodimeric form of 3CLpro enzyme for its inhibitory activity. In summary, these molecules could be useful to develop highly specific therapeutically viable drugs to inhibit the SARS-CoV-2 replication either alone or in combination with drugs specific for other SARS-CoV-2 viral targets.
Authors: James C Phillips; David J Hardy; Julio D C Maia; John E Stone; João V Ribeiro; Rafael C Bernardi; Ronak Buch; Giacomo Fiorin; Jérôme Hénin; Wei Jiang; Ryan McGreevy; Marcelo C R Melo; Brian K Radak; Robert D Skeel; Abhishek Singharoy; Yi Wang; Benoît Roux; Aleksei Aksimentiev; Zaida Luthey-Schulten; Laxmikant V Kalé; Klaus Schulten; Christophe Chipot; Emad Tajkhorshid Journal: J Chem Phys Date: 2020-07-28 Impact factor: 3.488
Authors: Pauline J van der Watt; Alicia Chi; Tamara Stelma; Catherine Stowell; Erin Strydom; Sarah Carden; Liselotte Angus; Kate Hadley; Dirk Lang; Wei Wei; Michael J Birrer; John O Trent; Virna D Leaner Journal: Mol Cancer Ther Date: 2016-02-01 Impact factor: 6.261
Authors: Alimuddin Zumla; Jasper F W Chan; Esam I Azhar; David S C Hui; Kwok-Yung Yuen Journal: Nat Rev Drug Discov Date: 2016-02-12 Impact factor: 84.694
Authors: Jonathan Grein; Norio Ohmagari; Daniel Shin; George Diaz; Erika Asperges; Antonella Castagna; Torsten Feldt; Gary Green; Margaret L Green; François-Xavier Lescure; Emanuele Nicastri; Rentaro Oda; Kikuo Yo; Eugenia Quiros-Roldan; Alex Studemeister; John Redinski; Seema Ahmed; Jorge Bernett; Daniel Chelliah; Danny Chen; Shingo Chihara; Stuart H Cohen; Jennifer Cunningham; Antonella D'Arminio Monforte; Saad Ismail; Hideaki Kato; Giuseppe Lapadula; Erwan L'Her; Toshitaka Maeno; Sumit Majumder; Marco Massari; Marta Mora-Rillo; Yoshikazu Mutoh; Duc Nguyen; Ewa Verweij; Alexander Zoufaly; Anu O Osinusi; Adam DeZure; Yang Zhao; Lijie Zhong; Anand Chokkalingam; Emon Elboudwarej; Laura Telep; Leighann Timbs; Ilana Henne; Scott Sellers; Huyen Cao; Susanna K Tan; Lucinda Winterbourne; Polly Desai; Robertino Mera; Anuj Gaggar; Robert P Myers; Diana M Brainard; Richard Childs; Timothy Flanigan Journal: N Engl J Med Date: 2020-04-10 Impact factor: 91.245
Authors: Mohamed Haddad; Roger Gaudreault; Gabriel Sasseville; Phuong Trang Nguyen; Hannah Wiebe; Theo Van De Ven; Steve Bourgault; Normand Mousseau; Charles Ramassamy Journal: Int J Mol Sci Date: 2022-02-27 Impact factor: 5.923
Authors: Francesco Costacurta; Stephan Geley; Seyad Arad Mogadashi; Andre Volland; Emmanuel Heilmann; Bernhard Rupp; Reuben Stewart Harris; Dorothee von Laer Journal: Commun Biol Date: 2022-04-27
Authors: Andrew Bryant; Theresa A Lawrie; Therese Dowswell; Edmund J Fordham; Scott Mitchell; Sarah R Hill; Tony C Tham Journal: Am J Ther Date: 2021-06-21 Impact factor: 2.688